ACTRN12605000699662进行中（未招募）2 期
Pilot Phase II Study of Sandostatin LAR in Patients with Advanced Hepatocellular Carcinoma to assess toxicity and improve survival
Site - Investigator Initiated0 个研究点目标入组 60 人开始时间: 2005年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •(All of the following): 4.1.1histological OR cytological evidence of hepatocellular carcinoma OR liver imaging suggestive of the diagnosis AND a plasma alpha-fetoprotein over 500 IU/mL. 4.1.2 Hepatocellular carcinoma which is unresectable. 4.1.3patient performance status (WHO) grade 0, 1 or 2.4.1.7women must have a negative pregnancy test prior to treatment; both men and women should have adequate contraception during the course of treatment.4.1.8written informed consent.
排除标准
- •(None of the following: )4.2.1Previous octreotide treatment for hepatocellular carcinoma4.2.2patient performance status > (WHO) 3 4.2.3peripheral blood white cell count < 2.0 x 109/L, platelet count <50 x 109/L and haemoglobin < 10.0 g/L.4.2.4serum creatinine greater than or equal to 0.15mmol/L; serum bilirubin > 50 micromol/litre; serum albumin < 25 g/L; AST and ALT > 5x institutional upper limit of normal. Patients with Primary Biliary Cirrhosis (PBC) should be classified using Bilirubin levels defined for this patient group in the Childs-Pugh Score (see appendix 7).4.2.5prothrombin ratio (INR) > 2.04.2.6any inter-current illness that may significantly interfere with safe administration of Sandostatin LAR® or end-point evaluation; including refractory severe encephalopathy, symptomatic gallstone disease (either cholecystolithiasis or choledocholithiasis).4.2.7Treatment with somatostatin for other reasons4.2.8Concurrent anti-tumour treatment for HCC4.2.9pregnant women4.2.10previous malignancy within the last 5 years other than curatively resected non-melanoma skin cancer or carcinoma of the uterine cervix.4.2.11known reaction to the study drug4.2.12HIV positive patients4.2.13uncontrolled ascites requiring paracentesis within 4 weeks4.2.14variceal bleeding in the last month4.2.15prior radiation therapy to the only evaluable site of disease4.2.16refusal to give informed consent to participate in the study4.2.17Child-Pugh class C cirrhosis, (for patients with PBC use the adjusted bilirubin levels to classify the patient).4.2.18patients who are rendered artificially eligible by the administration of blood product support.
研究者
相似试验
进行中（未招募）
1 期
Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR.EUCTR2014-003856-30-BECliniques Universitaires Saint Luc50
终止
2 期
Sandostatin for Patients With Androgen Independent Prostate CancerProstate CancerNCT00510224University of California, San Francisco13
进行中（未招募）
1 期
Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancerThe population includes all patients who must have an axillary node dissection for non-metastatic breast cancer.EUCTR2015-004337-27-FRInstitut de Cancérologie de l'Ouest67
已完成
4 期
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsAcromegalyNCT01278342Novartis Pharmaceuticals70
进行中（未招募）
不适用
Sandostatin LAR in prevention of Chemotherapy Induced DiarrheaEUCTR2006-001150-27-BEniversity Hospital Gent